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Table 1 Characteristics of included observational studies  
Study Study 
design 
Study 
period 
Region Data ascertainment Inclusion criteria Exclusion criteria Outcome 
ascertainment 
Abraham 
2015[37] 
R, C Nov 2010-
Sep 2013 
USA Medical and pharmacy 
administrative claims from 
Optum Labs Data 
Warehouse 
≥18y,  received dabigatran, 
rivaroxaban or warfarin on the 
index date  
Patients had Rx for targeted treatment ≤12 
months before index date; did not have 
continuous enrolment; with mechanical 
heart valve or mitral stenosis, chronic 
haemodialysis or peritoneal dialysis and 
kidney transplant; residing in skilled 
nursing facility or nursing home 
ICD-9 
codes  
Chan 
2015[38] 
 
 
P, C Oct 2010-
Oct 2014 
USA Fresenius Medical Care 
North America (FMCNA) 
ESRD database 
Chronic haemodialysis patients 
with AF who started de novo OAC 
Patients with a previous diagnosis of 
warfarin skin necrosis, protein S deficiency, 
protein C deficiency, or calciphylaxis 
 
Medical 
records 
Chang 
2015[39] 
R, C Oct 2010- 
Mar 2012 
USA IMS Health LifeLink Health 
Plan Claims Database 
≥18y; continuous enrolment in six 
months before the entry date; 
receive none NOAC at base line; 
without bleeding history 
Not reported ICD-9 
codes  
Graham 
2015[26] 
R, C Oct 2010-
Dec 2012 
USA Claim files from Medicare 
beneficiaries enrolled for 
Medicare program 
Patient Aged ≥65y with AF or atrial 
flutter who newly received ≥1 Rx 
for dabigatran or warfarin; having 
≥6 months of enrolment in 
Medicare before index date 
In a skilled nursing facility or hospice at 
index, hospitalization that extended beyond 
the index dispensing date; undergoing 
dialysis/kidney transplant; with mitral valve 
disease, heart valve repair or replacement, 
VTE, or joint replacement surgery in the 
preceding 6 months 
ICD-9 
codes 
Hernandez 
2015[40] 
R, C Oct 2010-
Oct 2011 
USA Pharmacy and medical 
claims of Medicare 
beneficiaries 
Newly diagnosed with AF, filled an 
outpatient Rx for dabigatran or 
warfarin within 2 months of the 
first diagnosis 
Filled prescriptions for dabigatran and 
warfarin during the first 2 months after 
diagnosis 
 
ICD-9 
codes 
Larsen 
2014[34] 
P, C dabigatran: 
Aug 2011- 
May 2013 
warfarin: 
Aug 2009- 
May 2013 
Denmark Danish National Prescription 
Registry 
Naïve dabigatran users/ any 
warfarin users during the study 
period, with a prior diagnosis of AF 
With a diagnoses of mitral stenosis, VTE, 
or valvular surgery; with a previous 
purchase of phenprocoumon 
ICD-10 
codes 
Staerk 
2015[43] 
R, C Aug 2011 
Dec 2012 
Denmark The Danish Civil 
Registration system; Danish 
National Patient Registry; 
Danish National Prescription 
Registry 
An OAC naive AF patient initiated 
first-time OAC or, a warfarin-
experienced AF patient initiated 
dabigatran  
Aged <30 or >100; with valvular disease, 
total hip or knee replacement surgery ≤ 8 
weeks or VTE ≤ 6 months before baseline; 
with GIB, gastroesophageal reflux, gastritis, 
gastric/duodenal ulcer, gastroscopy, and PPI 
use 180 days before baseline 
ICD-10 
codes 
Larsen 
2013[32] 
P, C Aug 2009-
Dec 2012 
 
Denmark The Danish Civil 
Registration system; Danish 
National Patient Registry; 
AF patients who were previously 
untreated (both warfarin and 
dabigatran) 
Not reported ICD-10 
codes  
Danish National Prescription 
Registry 
Lauffenbur
ger 
2015[41] 
R, C  2009-2012 USA Truven Health MarketScan 
Commercial Claims and 
Encounters and Medicare 
supplement database 
AF patients ≥18y and continuously 
enrolled for ≥ 12 months before 
index date, filling ≥1 Rx for 
warfarin or dabigatran 
Anticoagulant Rx filled in the 12 months 
prior to the index date, with valvular or 
transient AF in the baseline period 
Validated 
ICD-9 
coding 
algorithms  
Vaughan 
Sarrazin 
2014[36] 
R, C June 2010-
June 2011,  
 
 
USA National Veterans Affairs 
administrative encounter and 
pharmacy data 
AF patients who received warfarin 
for ≥180 days within study period, 
with the most recent fill date≤ 90d 
before June 2011 
 
Without a diagnosis of AF during the 12 
months before June 2011; with a GFR <30 
mL/min/1.73m
2
 during the prior 12 months 
or with a prosthetic heart valve 
Validated 
ICD-9 
codes  
Laliberte 
2014[33] 
R, C May 2011- 
July 2012. 
 
 
USA Symphony Health 
Solutions’ (SHS) Patient 
Transactional Datasets 
AF patients ≥18y newly initiated on 
rivaroxaban or warfarin after Nov 
2011; CHADS2 score≥1 during the 
180 days baseline period, ≥6months 
of clinical activity 
Patients diagnosed at baseline with valvular, 
pregnancy, malignant cancers and transient 
causes of AF 
ICD-9 
codes 
Bell 
2013[31] 
P, CS Jul 2011- 
Jun 2012 
New 
Zealand 
Medical records from ACH 
Emergency Department in 
Auckland, City Hospital 
Patients admitted with upper GIB 
and concurrent warfarin or 
dabigatran therapy 
Not reported Hospital 
admission 
records 
Choi 
2014[60] 
P, CS Sept 2011- 
Nov 2011 
USA The National Health and 
Wellness Survey, Lightspeed 
Research Internet panel, 
Telephone databases of AF 
patients 
Patients ≥18years with self-reported 
AF diagnosed by healthcare 
provider, had used warfarin or 
dabigatran as stroke prophylaxis. 
Less technologically able patients Self-
reported 
Sherid 
2015[42] 
 
R, CS Oct 2010- 
Oct 2012 
USA Medical records from CGH 
Medical Center in Sterling, 
Ill. & Saint Francis Hospital 
in Evanston, Ill. 
Patients aged ≥18 y taking either 
dabigatran for ≥3 days or 
rivaroxaban for ≥4 days 
An unknown duration of rivaroxaban and 
dabigatran, lack of follow-up, with 
pregnancy, mechanical valve replacement 
and advanced kidney disease (GFR 
<15ml/min/1.73 m
2
) or end-stage renal 
disease on dialysis 
Medical 
records 
Nagao 
2015[45] 
R, CS Apr 2013-
Mar 2014 
Japan Medical records from 
Nagoya University Hospital,  
Patients who received warfarin or 
apixaban, and underwent 
radiofrequency catheter ablation for 
AF 
Not reported Medical 
records 
Sherid 
2014[35] 
 
R, CS Oct 2010- 
Apr 2013 
 
USA Medical records from CGH 
Medical Center in Sterling, 
Ill. & Saint Francis Hospital 
in Evanston, Ill. 
Patients aged ≥18 y taking either 
dabigatran for ≥3 days or 
rivaroxaban for ≥4 days 
An unknown duration of rivaroxaban and 
dabigatran, lack of follow-up, pregnancy, 
mechanical valve replacement and 
advanced kidney disease (GFR <15 
ml/min/1.73 m
2
 or end-stage renal disease 
on dialysis) 
Medical 
records 
Abbreviations: ACH= Auckland City Hospital; AF=atrial fibrillation; C=cohort; CS=cross-sectional; FDA=Food and Drug Administration; GFR= glomerular 
filtration rate; GI=gastrointestinal; GIB=gastrointestinal bleeding; ICD-9=International Classification of Diseases, Ninth Revision; P=prospective; 
R=retrospective; VTE=venous thromboembolism; OAC=oral anticoagulation; Rx=prescription; IMS=Intercontinental Marketing Services; ESRD=end-stage 
renal disease; Y=years; CHADS2=congestive heart failure, hypertension, age of 75 years or older, diabetes mellitus, prior stroke or transient ischemic attack or 
thromboembolism; PPI=proton pump inhibitor
Table 2 Subgroup and sensitivity analyses of the GIB risk among users of NOAC vs warfarin 
Sensitivity analyses Comparison groups No. of 
studies 
Adjusted estimate 
(95%CI) 
Heterogeneity 
between studies 
Sensitivity analysis 1
a
 dabigatran vs warfarin 
7 
1.30 (1.01-1.66) 
P<0.00001, 
I
2
=91% 
Sensitivity analysis 2
b
 dabigatran vs warfarin 
7 
1.24 (0.98-1.59) 
P<0.00001, 
I
2
=91% 
Sensitivity analysis 3
c
 dabigatran vs warfarin 
6 
1.27 (1.13-1.41) 
P=0.09, 
I
2
=48% 
Sensitivity analysis 4
d
 
dabigatran vs warfarin 6 1.18 (1.02-1.36) P=0.004, I
2
=71% 
rivaroxaban vs warfarin 4 1.10 (0.87-1.38) P=0.28, I
2
=22% 
Subgroup analyses No. of 
studies 
Adjusted estimate 
(95%CI) 
Heterogeneity 
between groups Variable Subgroups 
Indication 
Dabigatran 
AF 6 1.21 (1.03-1.42) 
P=0.99, I
2
=0% Non-AF 1 1.14 (0.54-2.39) 
Non-specified 1 1.21 (0.96-1.53) 
Rivaroxaban 
AF 3 1.08 (0.87-1.35) 
P=0.70, I
2
=0% Non-AF 1 0.89 (0.60-1.32) 
Non-specified 1 0.98 (0.36-2.69) 
GIB severity  
Dabigatran 
Major 2 1.30 (1.17-1.46) 
P=0.33, 
I
2
=10.3% 
Non-major 1 0.85 (0.40-1.79) 
Any 5 1.15 (0.95-1.40) 
Rivaroxaban 
Major 1 0.96 (0.58-1.59) 
P=0.78 
I
2
=0% 
Non-major 1 0.82 (0.30-2.22) 
Any 3 1.10 (0.87-1.38) 
Patient age 
Dabigatran  
18-64y 1 1.34 (0.98-1.83) 
P=0.63 
I
2
=0% 
≥ 65y 3 1.46 (0.99-2.13) 
All adults ≥ 18y 6 1.21 (1.00-1.45) 
Rivaroxaban 
18-64y 1 1.03 (0.33-3.18) 
P=0.92 
I
2
=0% 
≥ 65y 2 1.49 (0.33-6.68) 
All adults ≥ 18y 4 1.09 (0.92-1.30) 
Prior use of 
warfarin  
Dabigatran 
Yes 2 1.40 (1.01-1.96) P=0.31 
I
2
=3.0% No 6 1.16 (1.01-1.34) 
NSAID Dabigatran 
Yes 5 1.20 (0.98-1.47) P=0.87 
I
2
=0% No 2 1.24 (0.94-1.63) 
Rivaroxaban 
Yes 3 1.10 (0.87-1.38) P=0.63 
I
2
=0% No 1 0.96 (0.58-1.59) 
 
PPI/H2 
Dabigatran Yes 4 1.11 (0.95-1.30) P=0.01 
I
2
=83.8% No 3 1.50 (1.25-1.80) 
Rivaroxaban Yes 2 0.93 (0.70-1.24) P=0.17 
I
2
=46.7% No 2 1.20 (0.96-1.50) 
Antiplatelet 
agents 
Dabigatran 
Yes 5 1.17 (0.99-1.40) P=0.43 
I
2
=0% No 2 1.31 (1.07-1.59) 
Rivaroxaban 
Yes 2 1.10 (0.81-1.49) P=0.64 
I
2
=0% No 2 0.96 (0.61-1.51) 
Steroid 
Dabigatran 
Yes 3 1.09 (0.83-1.43) P=0.26 
I
2
=20.9% No 4 1.33 (1.07-1.64) 
Rivaroxaban 
Yes 2 0.93 (0.70-1.24) P=0.17 
I
2
=46.7% No 2 1.20 (0.96-1.50) 
SSRI 
Dabigatran 
Yes 2 1.02 (0.64-1.64) P=0.37 
I
2
=0% No 5 1.28 (1.10-1.50) 
Rivaroxaban 
Yes 1 0.93 (0.69-1.25) P=0.19 
I
2
=42.4% No 3 1.19 (0.96-1.48) 
a
 substitution of Larsen 2014’s results [34] with that of Staerk 2015[43], and Graham 2015’s results [26] with that of 
Hernandez 2015[40], respectively 
b
 substitution of Larsen 2014’s results [34] with that of Larsen 2013[32], and Graham 2015’s results [26] with that of 
Hernandez 2015[40], respectively 
c
 exclusion of the result of Abraham 2015 [37] 
d
 exclusion of the result of Chan 2015 [38] 
Abbreviations: NOAC= non-vitamin K antagonist oral anticoagulants; GIB=gastrointestinal bleeding; PPI=proton 
pump inhibitor; H2RA=histamine type-2 antagonists; NSAID=non-steroidal anti-inflammatory drug; Riva=rivaroxaban; 
Dabi=dabigatran; Warf=warfarin; RR=risk ratio; CI=confidence interval; SSRI=selective serotonin reuptake inhibitor 
